Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Blood Advances|February 11, 2021
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphomaJohn H Baird, David J Epstein, John S Tamaresis, et al.
Blood Cancer Journal|April 4, 2026
Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapyMasooma Shifa Rana, Sebastian Fernandez-Pol, Alexandria Jensen, et al.
Cancer Discovery|January 8, 2025
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCLYi-Jiun Su, Anne Marijn Kramer, Mark P Hamilton, et al.
Journal for Immunotherapy of Cancer|July 2, 2024
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphomaSushma Bharadwaj, Eric Lau, Mark P Hamilton, et al.
The Journal of Experimental Medicine|June 20, 2020
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trialMatthew J Frank, Michael S Khodadoust, Debra K Czerwinski, et al.
Blood Advances|July 24, 2025
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysisNausheen Ahmed, Swetha Thiruvengadam, Mehdi Hamadani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T ConsortiumYucai Wang, Preetesh Jain, Frederick L Locke, et al.
Blood Advances|March 18, 2024
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicityMark P Hamilton, Erin Craig, Cesar Gentille Sanchez, et al.
Nature Medicine|September 13, 2022
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapyZinaida Good, Jay Y Spiegel, Bita Sahaf, et al.
Blood|July 5, 2024
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemiaHrishikesh Srinagesh, Clayton Jackson, Parveen Shiraz, et al.
Pageof 5